- Home
- WRN vs CLLS Comparison
WRN vs CLLS Comparison
Compare WRN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.56
HOLD
Current Price
$3.46
Company Overview
Basic Information| Metric | WRN | CLLS |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 676.9M | 384.3M |
| IPO Year | 2006 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WRN | CLLS |
|---|---|---|
| Price | $2.56 | $3.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.88 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 1.7M | 41.3K |
| Earning Date | 05-08-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $40.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $1.10 |
| 52 Week High | $4.26 | $5.48 |
Technical Indicators
Market Signals| Indicator | WRN | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 35.83 | 41.67 |
| Support Level | $1.20 | $3.41 |
| Resistance Level | $2.56 | $3.83 |
| Average True Range (ATR) | 0.18 | 0.21 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 2.06 | 20.00 |
Price Performance
Historical Comparison WRN
CLLS
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.